- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01585688
Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL
A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Helen F. Graham Cancer Center
-
-
Florida
-
Orlando, Florida, United States, 32806
- MD Anderson Cancer Center Orlando
-
-
Indiana
-
Goshen, Indiana, United States, 46526
- IU Health Goshen Center for Cancer Care
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01605
- UMass Memorial Cancer Center of Excellence
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- John Theurer Cancer Center Hackensack University Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- U.T. MD Anderson Cancer Center Houston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age ≥ 18 years
- Able to provide signed, informed consent
- Histologically confirmed diagnosis of recurrent B-cell non-Hodgkin's lymphoma (any histology by WHO criteria) or recurrent chronic lymphocytic leukemia (by NCI criteria) (Reference Appendix C)
- Received at least one prior treatment with standard therapy (previous antibody therapy is acceptable)
- Measurable disease at least one lesion ≥ 1.5 cm for NHL and ALC > 5,000 for CLL
Adequate performance status (≥ 70 Karnofsky scale) with an estimated life expectancy of at least 6 months
--Documented negative hepatitis B screen, per NCCN guidelines (hepatitis B surface antigen/antibodies, core antigen/antibodies, hepatitis B e-antigen)
- At least 12 weeks beyond stem cell transplant and 4 weeks beyond chemotherapy or immunotherapy, major surgery, other experimental treatments, or radiation therapy to the index lesions, and with all acute toxicities from prior therapy resolved to less than Grade 2 toxicity by NCI CTC version 4.0
- Laboratory parameters:
Adequate hematology without ongoing transfusional support Hemoglobin >/= 10 g/dL Absolute neutrophil count >/= 1.5 x 10 9/L Platelets >/= 75 x 10 9/L Creatinine and bilirubin </= 1.5 x IULN AST and ALT </= 2.5 x IULN
-Adequate cardiac function (MUGA scan or 2-D ECHO with LVEF ≥ 55%, EKG with no medically relevant arrhythmia uncontrolled on medications)
Exclusion Criteria:
- -Pregnant or lactating women. Women of childbearing potential must have a negative pregnancy test. Pregnancy testing is not required for post-menopausal or surgically sterilized women.
- Women of childbearing potential and fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study until at least 12 weeks after the last milatuzumab infusion
- Prior therapy with other human or humanized monoclonal antibodies, unless HAHA tested and negative
- Prior treatment with trastuzumab
- Bulky disease by CT, defined as any single mass > 10 cm in its greatest diameter
- Known HIV positive or active hepatitis B or C, or presence of hepatitis B surface antigens or presence of hepatitis C antibody
- New York Heart Classification III or IV heart disease (see Appendix G). Other severe cardiovascular or cardiopulmonary disease, including COPD
- Baseline BNP > 2 x IULN
- Patients with uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities will be excluded
- Patients with recent (≤ 6 months) cardiac angina, difficult to control congestive heart failure, uncontrolled hypertension, or difficult to control cardiac arrhythmias will be excluded
- Known autoimmune disease or presence of autoimmune phenomena
- At least 7 days beyond any infection requiring intravenous antibiotic use (Oral antibiotics may be administered prophylactically as clinically indicated)
- Systemic corticosteroids within 2 weeks, except low dose regimens (prednisone, ≤ 20 mg/day, or equivalent) which may continue if unchanged
- Substance abuse or other concurrent medical or psychiatric conditions that, in the Investigator's opinion, could confound study interpretation or affect the patient's ability to tolerate or complete the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: hLL1-DOX
|
hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the safety and tolerability of hLL1-DOX
Time Frame: These assessments will be done routinely during treatment & changes at 4, 8 & 12 weeks after treatment
|
NCI CTCAE version 4.0 is used to grade all adverse events
|
These assessments will be done routinely during treatment & changes at 4, 8 & 12 weeks after treatment
|
All patients who were treated and meet the efficacy criteria for response assessment will be included in the analysis of efficacy
Time Frame: During treatment and the changes at 4, 8 and 12 weeks after treatment and then every 3 months for up to 2 years
|
For the primary efficacy evaluations, the proportion of responders (defined as patients with a best response of PR or CR) will be tabulated for each dose level. In addition, the progression-free survival (PFS, as measured from start of treatment to disease progression, death or last follow-up) will be summarized using Kaplan-Meier survival analysis methods. Similarly, for responders at each dose level, the duration of response (DR, as measured from time of first response to relapse or last follow-up) will also be summarized using Kaplan- Meier survival analysis methods, if appropriate. |
During treatment and the changes at 4, 8 and 12 weeks after treatment and then every 3 months for up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Pius P Maliakal, PhD, Gilead Sciences
- Study Chair: Francois Wilhelm, MD,PhD, Gilead Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IM-T-hLL1-DOX-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
SCRI Development Innovations, LLCBiogenCompleted
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
Clinical Trials on hLL1-DOX (IMMU-115)
-
Gilead SciencesCompletedChronic Lymphocytic LymphomaUnited States
-
Gilead SciencesCompletedMultiple Myeloma | Myeloma, Plasma-Cell | PLASMACYTOMAUnited States
-
Gilead SciencesOhio State UniversityTerminatedMyelodysplastic Syndrome | Chronic Myelogenous Leukemia (CML) | Multiple Myeloma (MM) | GVHD (Acute or Chronic) | Acute Myeloid or Lymphoblastic Leukemia (AML or ALL) | Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell) | Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia...United States
-
Gilead SciencesTerminatedMultiple MyelomaUnited States